SERPASIL-APRESOLINE
LOE ApproachingNDAORALTABLET
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL-APRESOLINE is a fixed-dose combination oral tablet approved in 1954 for hypertension management. The product combines reserpine and hydralazine, two small-molecule antihypertensive agents with complementary mechanisms. It represents a legacy antihypertensive therapy from the pre-modern era of blood pressure control.
LOE Approaching
Minimal commercial activity expected; team focused on lifecycle management and legacy patient retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SERPASIL-APRESOLINE offers limited growth opportunity but provides valuable experience in lifecycle management, legacy product stewardship, and niche market strategy. This role is best suited for professionals seeking stable, specialized expertise in mature therapeutics rather than launch-phase or growth-stage careers.
Product Manager (Legacy)Medical Science Liaison
Worked on SERPASIL-APRESOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.